Cannabis Pharmaceuticals Inc. (OTCMKTS:CNBX) commenced expansion in the European markets to offer cancer patients tailored cannabinoid treatment tests based on the company’s diagnostic platform in jurisdictions where regulations allow.
HTS diagnostic platform helping in tailoring cannabinoid treatments
This comes as the number of European countries permitting the medicinal use of cannabis products continues to grow each day. The increasing number of cancer patients in Europe that need cannabinoid treatments also necessitated the company’s move. Cannabis Pharmaceuticals is strategically focusing its efforts to ensure its HTS diagnostic platform is accessible across the continent. The company intends to carry out more clinical studies so that it can meet this milestone.
Cannabis Pharmaceutical’s HTS diagnostic platform uses the Israeli-based High Throughput Screening facility for the trials. The platform is designed for patients with cancer seeking optimal cannabinoid composition. The test involves getting cancer cells and screening them against various cannabinoid compositions offered in the patient’s jurisdiction. After exposing the cancer cells to cannabinoid compositions they are then monitored for necrotic and apoptotic effects. They then send the results to the patients and physicians to help pick appropriate cannabinoid therapy that can offer optimal results.
There is a massive opportunity in Europe from cannabinoid therapies
World Health Organisation issued a report last year indicating that over 58,000 colorectal cancer cases were reported annually in Germany. As a result, based on previous pre-clinical results that showed differential necrotic effects on colorectal cancer cells using Cannabinoids, the company has moved to expand its penetration in Europe. The focus will be on gastrointestinal tract cancer patients.
The company was delighted to expand its reach in Europe to countries where it is legal to sell medicinal cannabis products. Chairman and Co-Founder, Itamar Borochov added that the company aims to offer valuable insights for tailoring cannabinoid-based treatment for cancer patients. He added that there is a massive opportunity in European markets as more countries allow medicinal use of CBD and THC products.
3 Big Biotech Disruptors For 2021
Post Views: 21,235
Post Views: 69,488 CBD market growth over the next ten years will outpace marijuana growth by more than 30-to-one By...
Stem Holdings Inc (OTCMKTS:STMH) Reports A Growth Of 960% In Q3 2020: Unveils TJGardens Branded Tinctures
Post Views: 1,392 Stem Holdings Inc (OTCMKTS:STMH) posted an increase of 960% YoY to $6.7 million in Q3 2020. It...
Indiva Ltd (OTCMKTS:NDVAF) Signs Three Provincial Agreements: Expands Distribution Network To Eight Provinces: Reports A Robust Growth Of 1273.7% In Q2 2020 Revenues
Post Views: 1,313 Indiva Ltd (OTCMKTS:NDVAF) posted a robust growth of 1273.7% YoY to CAD 2.826 million in revenues in...
4Front Ventures Corp (OTCMKTS:FFNTF) Receives Approval From CCC For Mission Dispensary and Cultivation Facilities In Worcester: Will Commence Adult-Use Cannabis Sales
Post Views: 1,323 CCC (Cannabis Control Commission) in Massachusetts approved cultivation and processing facilities and Mission Dispensary of 4Front Ventures...
Pure Sunfarms, A Joint Venture Of Village Farms International Inc (NASDAQ:VFF), Ships Bottled Oil Products TO British Columbia
Post Views: 1,425 Pure Sunfarms, which is a Village Farms International Inc (NASDAQ:VFF) JV, commenced shipment of Cannabis 2.0 products...